● neutral
Impact
PhaseApproved (marketed); new Phase 3 label-expansion trial (SIGMA) just begun enrolling
Time to marketAlready on the market (approved and commercialized). Label expansion into secondary immunodeficiency is estimated years away — readouts likely 2-3 years out per company commentary.
GAMUNEX-C immune globulin intravenous (human) Updated Aug 18
What to watch
For Grifols (GRFS), Gamunex-C is a core revenue asset but not a near-term stock catalyst, the share-price drivers in the next ~12 months are company-wide (SPARTA Prolastin-C topline expected by end-2026, quarterly results), not Gamunex-C-specific. Watch SIGMA/XPERT enrollment updates for optionality, but treat the label-expansion payoff as a 2028+ event. Note the tape is mixed: positive analyst consensus and Q2 2026 13F accumulation by several managers, but also high short-volume flow and multiple 13F trims/exits.
Bull case
- Already-approved, marketed flagship product generating revenue today; Grifols calls GAMUNEX-C and XEMBIFY its 'flagship immunoglobulins' and cites XEMBIFY growing nearly 60% YoY in 2025 as evidence of strong Ig-franchise demand (July 16, 2026 press release).
- New Phase 3 SIGMA trial targets secondary immunodeficiency in hematologic cancers, a population of >1 million U.S. patients with CLL, MM and NHL, a meaningful label-expansion opportunity if it succeeds (press release report key facts).
- Analyst setup positive: consensus 9 Buy + 5 Strong Buy vs 2 Sell/5 Hold, and mean price target $10.865 vs $7.75 last price (~40.2% implied upside), though based on only 2 analysts' targets.
Bear case
- No near-term binary for THIS drug: SIGMA/XPERT are just starting enrollment (first dose July 2026) with readouts estimated 2-3 years out, so label-expansion revenue is far away (press release report actionableInsight).
- Phase 3 and regulatory risk: trial failure or enrollment delays could derail label expansion, and Ig products carry safety risks such as thrombotic events (press release report risk list).
- Competition: CSL Behring, Takeda and others market competing immunoglobulin therapies that could limit share gains even if labels expand (press release report risk list).